GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the second quarter ended June 30, 2026, and provided a business update highlighting progress toward initiating a pivotal immunobridging study for its GEO-MVA vaccine candidate under an expedited regulatory pathway. The company also continues to advance its Gedeptin immuno-oncology program.
During the quarter, GeoVax advanced multiple operational initiatives supporting the expected fourth-quarter initiation of the GEO-MVA pivotal immunobridging study, following formal Scientific Advice discussions with the European Medicines Agency (EMA). These activities included continued clinical study readiness, manufacturing preparedness, and engagement with government and public health stakeholders regarding orthopoxvirus vaccine supply.
“During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study,” said David A. Dodd, Chairman and CEO of GeoVax. “Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.”
GeoVax reported a net loss of $4,426,578 ($0.97 per share) for the quarter, compared to $5,369,783 ($8.74 per share) in the same period last year. For the six-month period, net loss was $9,688,499 ($2.94 per share), compared to $10,727,434 ($19.72 per share) in 2025. The company reported no revenue from government contracts in 2026, compared to $852,282 in the second quarter of 2025, due to the termination of its BARDA contract for the GEO-CM04S1 COVID-19 vaccine program in April 2025.
Research and development expenses decreased to $3,110,508 for the quarter from $4,728,998 in the prior year, reflecting lower costs from discontinued BARDA activities and reduced spending on GEO-CM04S1. General and administrative expenses were $1,331,564, down from $1,542,190, primarily due to lower investor relations costs and stock-based compensation. Cash and cash equivalents stood at approximately $3.1 million as of June 30, 2026, unchanged from December 31, 2025.
In May 2026, GeoVax announced a strategic reprioritization to focus on GEO-MVA and Gedeptin, discontinuing active development of its COVID-19 vaccine candidate due to market contraction. The decision was not related to safety or efficacy concerns.
“At the same time, we continued advancing Gedeptin as an innovative immuno-oncology platform with the potential to enhance immune checkpoint inhibitor therapy,” Dodd added. “Our primary objective remains successful execution of the GEO-MVA program while continuing to build long-term value across two strategically important areas of healthcare.”
GeoVax is prioritizing resources toward programs offering strong clinical differentiation, regulatory clarity, and commercial opportunity, including the GEO-MVA pivotal study, scalable manufacturing capabilities, and Gedeptin combination strategies. Additional information is available in the company’s Quarterly Report on Form 10-Q filed with the SEC.
